Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor.

Liu L, Wang W, Yang L, Ren H, Kimata JT, Zhou P.

J Virol. 2013 Feb;87(3):1899-905. doi: 10.1128/JVI.01038-12. Epub 2012 Nov 14.

PMID:
23152526
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.

Liu L, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT, Zhou P.

J Virol. 2011 Sep;85(17):8467-76. doi: 10.1128/JVI.00520-11. Epub 2011 Jun 29.

PMID:
21715497
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR, Barbas CF 3rd.

J Virol. 2013 May;87(9):4985-93. doi: 10.1128/JVI.03146-12. Epub 2013 Feb 20.

PMID:
23427154
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike.

Wen M, Arora R, Wang H, Liu L, Kimata JT, Zhou P.

Retrovirology. 2010 Oct 6;7:79. doi: 10.1186/1742-4690-7-79.

PMID:
20923574
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11483-8. doi: 10.1073/pnas.1004600107. Epub 2010 Jun 2.

PMID:
20534513
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD.

J Virol. 2010 Aug;84(16):8098-110. doi: 10.1128/JVI.00966-10. Epub 2010 Jun 10.

PMID:
20538861
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.

Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR.

J Virol. 2011 May;85(9):4578-85. doi: 10.1128/JVI.02585-10. Epub 2011 Feb 16.

PMID:
21325411
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Davenport TM, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G, Kraft Z, Strong RK, Stamatatos L.

J Virol. 2011 Jul;85(14):7095-107. doi: 10.1128/JVI.00411-11. Epub 2011 May 4.

PMID:
21543501
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA.

Retrovirology. 2010 Feb 16;7:11. doi: 10.1186/1742-4690-7-11.

PMID:
20158904
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.

PMID:
21158699
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.

Thenin S, Roch E, Samleerat T, Moreau T, Chaillon A, Moreau A, Barin F, Braibant M.

J Gen Virol. 2012 Jul;93(Pt 7):1495-505. doi: 10.1099/vir.0.042614-0. Epub 2012 Apr 4.

PMID:
22492917
[PubMed - indexed for MEDLINE]
Free Article
12.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

PMID:
21849977
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.

Briney BS, Willis JR, Crowe JE Jr.

PLoS One. 2012;7(5):e36750. doi: 10.1371/journal.pone.0036750. Epub 2012 May 9.

PMID:
22590602
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I, Lopalco L, Tuffery P, Bomsel M.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12680-5. doi: 10.1073/pnas.1200024109. Epub 2012 Jun 20.

PMID:
22723360
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Doores KJ, Burton DR.

J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.

PMID:
20686044
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS.

J Virol. 2004 Sep;78(17):9233-42.

PMID:
15308718
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization.

Huarte N, Lorizate M, Pérez-Payá E, Nieva JL.

Curr Top Med Chem. 2011 Dec;11(24):2985-96. Review.

PMID:
22044227
[PubMed - indexed for MEDLINE]
18.

Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.

Chen W, Dimitrov DS.

Curr Opin HIV AIDS. 2009 Mar;4(2):112-7. doi: 10.1097/COH.0b013e328322f95e. Review.

PMID:
19339949
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.

Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK.

PLoS One. 2013 Dec 2;8(12):e80562. doi: 10.1371/journal.pone.0080562. eCollection 2013.

PMID:
24312481
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.

Ringe R, Phogat S, Bhattacharya J.

Virology. 2012 Apr 25;426(1):34-41. doi: 10.1016/j.virol.2012.01.011. Epub 2012 Feb 6.

PMID:
22314018
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk